This site is intended for healthcare professionals
  • Home
  • /
  • Clinical trials
  • /
  • Cosentyx
  • /
  • A Randomized, Double-blind, Placebo Controlled, Mu...
Clinical trial

A Randomized, Double-blind, Placebo Controlled, Multicenter Study of Subcutaneous Secukinumab to Demonstrate Efficacy After Twelve Weeks of Treatment, and to Assess the Safety, Tolerability and Long-term Efficacy up to One Year in Subjects With Moderate t

Read time: 2 mins
Last updated:1st Apr 2013
Identifier: NCT01365455
This study will assess the safety and efficacy of secukinumab compared to placebo in patients that have moderate to severe, chronic, plaque-type psoriasis.

 

Category Value
Date last updated at source 2016-01-19
Study type(s) Interventional
Expected enrolment 738
Study start date 2013-04-01
Estimated primary completion date 2013-04-01

View full details